Osteonecrosis of the jaw (ONJ) is one of the most relevant and specific complication of biphosphonates. ONJ in patients receiving zoledronic acid every 3 to 4 weeks is frequently described, but the ONJ biyearly regimen used to reduce aromatase inhibitor associated bone loss (AIBL), is rarely reported. A literature review, focusing on the important trials using zoledronic acid to reduce AIBL, found that the mean risk of developing ONJ when zoledronic acid is used biyearly varies between 0.12
作者：Hampig Raphael, Kourie；Joelle, Antoun；Elie, El Rassy；Marc, Rassy；Claude, Sader-Ghorra；Joseph, Kattan
来源：Journal of bone oncology 2015 年 4卷 3期
